PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a new biopharmaceutical company focused on advancing immuno-oncology therapeutics, announced that the Biotechnology Innovation Organization (BIO) has named the Company "Buzz of BIO" winner in the "Early Stage Entrepreneurs" category. In recognition of the Company's tremendous achievements as a newly established biopharmaceutical company, BIO has invited Dr. Charlene Liao, Chief Executive Officer of Immune-Onc to present at the 2017 BIO Investor Forum to be held on October 17-18, 2017 in San Francisco, California.
Immune-Onc was founded in 2016 and is focused on advancing novel immuno-oncology products to bring new treatment options to cancer patients. By leveraging strategic collaborations with leading investigators from Albert Einstein College of Medicine, the University of Texas and other institutions the company has made significant progress in building a promising pipeline of therapeutic antibodies targeting immune suppressive cell types or pathways in the tumor microenvironment.
"It is a great honor to be recognized by BIO, the world’s largest biotechnology trade association and a champion for the biotechnology industry," said Charlene Liao, Ph.D., Co-Founder and CEO of Immune-Onc. "We have made great strides in advancing our product portfolio towards the clinic and I look forward to sharing our latest achievements at the upcoming BIO Investor Forum."
BIO is the largest biotechnology trade association in the world, representing life sciences related companies and organizations across the United States and in more than 30 other nations. BIO is the organizer of the BIO Investor Forum, a highly anticipated international biotech investor conference focused on investment trends and business development opportunities in life sciences. The forum has over 880 attendees representing over 500 companies worldwide. Buzz of BIO is a contest organized by BIO to recognize the most innovative companies at the 2017 BIO Investor Forum.
Dr. Charlene Liao will be presenting at the 2017 BIO Investor Forum on Wednesday October 18th at 9:15 am PT in Elizabethan A of Westin St. Francis Hotel. This is the first public presentation of Immune-Onc, and Dr. Liao will be sharing the company’s key corporate objectives and showcasing the company’s pipeline progress.
To learn more about BIO, please visit: www.bio.org.
About Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. ("Immune-Onc") is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients. The company was founded in 2016 with headquarters in Palo Alto, California. www.immune-onc.com.